BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Debnath P, Chandnani S, Rathi P, Nair S, Junare P, Udgirkar S, Singh A, Contractor Q. A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus. Clin Exp Hepatol 2020;6:253-62. [PMID: 33145432 DOI: 10.5114/ceh.2020.99525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Taneja S, Duseja A, Mehta M, De A, Verma N, Premkumar M, Dhiman RK, Singh V, Singh MP, Ratho RK, Ramachandran R, Kumar V, Kohli HS. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021;41:705-709. [PMID: 33025685 DOI: 10.1111/liv.14685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Anand AC, Agarwal SK, Garg HK, Khanna S, Gupta S. Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation. J Clin Exp Hepatol 2017;7:165-71. [PMID: 28970701 DOI: 10.1016/j.jceh.2017.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
5 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Jalilian S, Latifi SM, Makvandi M, Teimoori A, Azaran A, Parsanahad M, Kayedani G. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection. Indian J Med Microbiol 2017;35:262-8. [PMID: 28681817 DOI: 10.4103/ijmm.IJMM_16_309] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterol 2018;5:e000209. [PMID: 30147941 DOI: 10.1136/bmjgast-2018-000209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, Sharma RK, Rai P, Aggarwal R. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton) 2019;24:316-21. [PMID: 29327401 DOI: 10.1111/nep.13222] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
9 Vyas BH, Darji NH, Rana DA, Vyas KY, Malhotra SD. Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients. Perspect Clin Res 2021;12:76-82. [PMID: 34012903 DOI: 10.4103/picr.PICR_123_19] [Reference Citation Analysis]
10 Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major. J Clin Exp Hepatol 2017;7:172-8. [PMID: 28970702 DOI: 10.1016/j.jceh.2017.08.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
11 Jain M. Hepatitis C treatment in the era of directly acting antivirals: an encouraging scenario. Trop Doct 2020;50:334-6. [PMID: 32631174 DOI: 10.1177/0049475520936878] [Reference Citation Analysis]
12 Goel A, Bhadauria DS, Kaul A, Prasad N, Gupta A, Sharma RK, Rai P, Aggarwal R. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol 2017;36:137-40. [PMID: 28345112 DOI: 10.1007/s12664-017-0745-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
13 Singh A, Kumari S, Kumar P, De A, Singh V. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. J Viral Hepat 2018;25:1501-6. [PMID: 30113115 DOI: 10.1111/jvh.12983] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
14 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Anand AC. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? J Clin Exp Hepatol. 2017;7:42-54. [PMID: 28348470 DOI: 10.1016/j.jceh.2017.01.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Bhushan A, Ghosh S, Bhattacharjee S, Chinnaswamy S. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. J Interferon Cytokine Res 2017;37:369-82. [PMID: 28727946 DOI: 10.1089/jir.2017.0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
17 Gupta A, Arora P, Jain P. Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India. J Clin Exp Hepatol 2018;8:116-20. [PMID: 29892172 DOI: 10.1016/j.jceh.2017.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]